Biopharmconsortium Blog

Expert commentary from Haberman Associates biotechnology and pharmaceutical consulting.

Monthly Archives: December 2013

Neuroscience companies sprout up in Boston

TweetIn our December 10, 2013 blog article that focused on Novartis’ new neuroscience division, we briefly mentioned two young Cambridge MA neuroscience specialty companies–Rodin Therapeutics and Sage Therapeutics. Rodin Therapeutics Rodin was founded by Atlas Venture and the German protein structure-focused biotech Proteros biostructures in June 2013. It is focused on applying epigenetics to discovery…

Will Novartis lead a pharma industry return to neuroscience R&D?

TweetA prominent feature of pharmaceutical company strategy in recent years has been massive cuts in R&D. These cutbacks have hit especially hard in areas that have not been productive in terms of revenue-producing drugs. Chief among the targets for R&D cuts and layoffs has been neuroscience. As outlined in a 2011 Wall Street Journal article,…

Zafgen makes progress in development of obesity drug beloranib

TweetOn November 15, 2013 obesity specialty company Zafgen (Cambridge, MA) announced the results of its Phase 2 study of beloranib in a press release. We discussed beloranib (ZGN-433) in our May 23, 2012 article on the Biopharmconsortium Blog. Beloranib is a methionine aminopeptidase 2 (MetAP2) inhibitor. Beloranib targeting of MetAP2 in vivo results in downregulation…